EUVIMEDEUVIMED entdecken
Leserbrief

Letter: Outcome Measure Selection as a Source of Null Results in Autism Pharmacotherapy: The Case of Brexpiprazole and the ABC-I

Berkan Şahin iD

Journal of Child and Adolescent Psychopharmacology · 01.08.2026 · 36 (6) · 382-383

DOI: 10.1177/10445463261453242 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Child and Adolescent Psychopharmacology, online erschienen am 20.05.2026. Verfasst von Berkan Şahin. Beteiligte Einrichtung: Department of Child and Adolescent Psychiatry, Faculty of Medicine, Giresun University, Giresun, Turkey. Die Arbeit nennt 14 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

the results of a Phase 3, randomized, double-blind, placebo-controlled trial and 26-week open-label extension of brexpiprazole for irritability associated with autism spectrum disorder (ASD) in children and adolescents aged 5 – 17 years

Autor:innen und Institutionen

  • Department of Child and Adolescent Psychiatry, Faculty of Medicine, Giresun University, Giresun, Turkey.

ORCID-Profile: Berkan Şahin

Zitieren

APA

Şahin, B. (2026). Letter: Outcome Measure Selection as a Source of Null Results in Autism Pharmacotherapy: The Case of Brexpiprazole and the ABC-I. Journal of Child and Adolescent Psychopharmacology, 36(6), 382-383. https://doi.org/10.1177/10445463261453242

Vancouver

Şahin B. Letter: Outcome Measure Selection as a Source of Null Results in Autism Pharmacotherapy: The Case of Brexpiprazole and the ABC-I. Journal of Child and Adolescent Psychopharmacology. 2026;36(6):382-383. doi:10.1177/10445463261453242

BibTeX
@article{ahin2026,
  author = {Şahin, Berkan},
  title = {Letter: Outcome Measure Selection as a Source of Null Results in Autism Pharmacotherapy: The Case of Brexpiprazole and the ABC-I},
  journal = {Journal of Child and Adolescent Psychopharmacology},
  year = {2026},
  volume = {36},
  number = {6},
  pages = {382--383},
  doi = {10.1177/10445463261453242}
}
Kostenlos starten →